Prostate cancer metastasis in young and middle-aged men


Cite item

Full Text

Abstract

For the first time detected prostate cancer in men up to the age of 60 years was identified in 638 patients, accounting for 9.4 percent of all patients with newly diagnosed metastatic prostate cancer before the age of 60 years. prostate cancer first identified before the age of 60 years, 20% of males has a metastatic nature. more than 73% of the patients are aged 54-59 years The localization of metastasis in men with newly diagnosed metastatic prostate cancer before the age of 60 years are the bones of the skeleton, more than 80% lesion is localized in the bones of the pelvis and lumbar spine.

About the authors

Dmitriy I. Ganov

Altai State Medical University; N.N. Blokhin Russian Cancer Research Center under the Russian Academy of Medical Sciences

Email: ganov2@rambler.ru
MD, PhD; Altay branch of N.N Blokhin Russian Cancer Research Center under the Russian Academy of Medical Sciences Barnaul, Russia Federation

S. A Varlamov

Altai State Medical University; N.N. Blokhin Russian Cancer Research Center under the Russian Academy of Medical Sciences

Altay branch of N.N Blokhin Russian Cancer Research Center under the Russian Academy of Medical Sciences Barnaul, Russia Federation

A. F Lazarev

Altai State Medical University; N.N. Blokhin Russian Cancer Research Center under the Russian Academy of Medical Sciences

Altay branch of N.N Blokhin Russian Cancer Research Center under the Russian Academy of Medical Sciences Barnaul, Russia Federation

References

  1. Чиссов В.И., Старинский В.В., Петрова Г.В., ред. Состояние онкологической помощи населению России в 2011 году. М.; 2012.
  2. Paulson D.F. Prostate Carcinoma. Philadelphia: Lea & Febiger; 1999.
  3. Cancel-Tassin G., Latil A., Valeri A., et al. PCAP is the maior known prostate cancer predisposing locus in families from sounth and west Europe. Eur. J. Hum. Genet. 2001; 9(2):135-42.
  4. Jemal A., Siegel R., Xu J. et al. Cancer statistics, 2010. CA. Cancer. J. Clin. 2010; 60: 277-300.
  5. Чиссов В.И., Русаков И.Г. Заболеваемость раком предстательной железы в Российской Федерации. Эксперементальная и клиническая урология. 2011: 2-3.
  6. Давыдов М.И., Аксель Е.М. Злокачественные новообразования в России и странах СНГ в 2005 г. М.: Медицинское информационное агентство; 2006.
  7. Boyle P., Ferlay J. Cancer incidence and mortality in Europe 2004. Ann. Oncol. 2005; 16: 481-8.
  8. Бормотин A.B., Говоров A.B.,Пушкарь Д.Ю. Алгоритм ранней диагностики рака предстательной железы. Русский медицинский журнал. 2003; 8: 13-6.
  9. Матвеев Б.П., ред. Клиническая онкоурология. М.: 2003.
  10. Gibbs M. Analysis of chromosome Ig 42.2-43 in 152 families with High risk of prostate cancer. Am. J. Genet. 1999 64; 1087-95.
  11. Kheirandish P., Chinegwundoh F. Ethnic differences in prostate cancer. Br. J. Cancer. 2011; 105(4): 481-5.
  12. Берштейн Л.М. Гормональный канцерогенез. СПб.: Наука; 2000.
  13. Welch H.G., Black W.C. Overdiagnosis in cancer. J. Natl. Cancer. Inst. 2010; 102: 605-13.
  14. Печерский А.В., Мазаров В.И. и др. Влияние уровня тестостерона на развитие рака предстательной железы. Онкоурология. 2005; 3: 31-8.
  15. Schroder F.H., Hugosson J., Roobol M.J. et al. Prostate-cancer mortality at 11 years of follow-up. N. Engl. J. Med. 2012; 366: 981-90.
  16. Русаков И.Г., Алексеев Б.Я. Лечение гормонорефрактерного рака предстательной железы. Современная онкология. 2004; 6: 34-6.
  17. Leitzmann M.F., Rohrmann S. Risk factors for the onset of prostatic cancer: age, location, and behavioral correlates. Clin. Epidemiol. 2012; (4): 1-11.

Copyright (c) 2014 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies